Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19
| Autor: | Zeynep G. Gul, Walid F. Gellad, Benjamin Davies, Inmaculada Hernandez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) SARS-CoV-2 business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Commerce MEDLINE COVID-19 medicine.disease Virus Erectile dysfunction Erectile Dysfunction Emergency medicine Pandemic Internal Medicine medicine Humans Proxy (statistics) business Concise Research Report |
| Zdroj: | Journal of General Internal Medicine |
| ISSN: | 1525-1497 0884-8734 |
| DOI: | 10.1007/s11606-021-06968-2 |
| Popis: | In response to the COVID-19 pandemic, most of the USA instituted lockdowns to minimize virus spread. As a result, cohabiting couples were quarantined together for several months, whereas those who lived apart and singles were discouraged from gathering. The effects of quarantining on sexual activity have been studied, primarily by surveys, most of which found that sexual activity decreased during the pandemic.1–4 To gain insight into the effects of COVID-19 on sexual activity, we examined the trend in national sales of phosphodiesterase-5 inhibitors (PDE5-Is), a proxy for sexual activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink